A phase I single centre 2-part open study to assess the safety and tolerability of AZD2171 following single and multiple oral doses in patients with advanced solid malignant tumours and liver metastases.

Trial Profile

A phase I single centre 2-part open study to assess the safety and tolerability of AZD2171 following single and multiple oral doses in patients with advanced solid malignant tumours and liver metastases.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jan 2011

At a glance

  • Drugs Cediranib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 20 Jan 2011 Actual end date (Feb 2006) added as reported by ClinicalTrials.gov.
    • 20 Jan 2011 Actual initiation date (Feb 2003) added as reported by ClinicalTrials.gov.
    • 13 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top